SEC Company Response from Oyster Point Pharma, Inc. (CIK 0001720725) — May 12, 2020
Oyster Point Pharma, Inc. (CIK 0001720725)
Date: May 12, 2020 · CIK: 0001720725 · Accession: 0001193125-20-140560
AI Filing Summary & Sentiment
File numbers found in text: 333-238194
Letter
202 Carnegie Center, Suite 109
Princeton, New Jersey 08540
VIA EDGAR
May 12, 2020
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards
Re: Oyster Point Pharma, Inc.
Registration Statement on Form S-1
File No. 333-238194
Ladies and Gentlemen:
Oyster Point Pharma, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-238194) (the “Registration Statement”) to become effective on Thursday, May 14, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Divakar Gupta and Ryan Sansom of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Ryan Sansom of Cooley LLP at (617) 937-2335.
[Signature page follows]
Very truly yours,
Oyster Point Pharma, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP 202 Carnegie Center, Suite 109 Princeton, New Jersey 08540 VIA EDGAR May 12, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Oyster Point Pharma, Inc. Registration Statement on Form S-1 File No. 333-238194 Ladies and Gentlemen: Oyster Point Pharma, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-238194) (the “Registration Statement”) to become effective on Thursday, May 14, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Divakar Gupta and Ryan Sansom of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Divakar Gupta of Cooley LLP, counsel to the Registrant, at (212) 479-6474, or in his absence, Ryan Sansom of Cooley LLP at (617) 937-2335. [Signature page follows] Very truly yours, Oyster Point Pharma, Inc. By: /s/ Jeffrey Nau Jeffrey Nau, Ph.D., M.M.S. President and Chief Executive Officer cc: Daniel Lochner, Oyster Point Pharma, Inc. Divakar Gupta, Cooley LLP Ryan Sansom, Cooley LLP Brandon Fenn, Cooley LLP Brian Cuneo, Latham & Watkins LLP Nathan Ajiashvili, Latham & Watkins LLP